Requiring either an EM rash or a CDC+ Western blot is a common eligibility criterion; however, this requirement reduced the PLD sample by 33% because many Lyme patients do not develop a rash or have a CDC+ Western blot result [35,41]. The gene discussed is GPLD1; the disease is erythema multiforme.